Quantcast
Last updated on April 17, 2014 at 11:49 EDT

Latest female sexual dysfunction Stories

2014-03-31 16:27:19

CRANBURY, N.J., March 31, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in...

2014-02-24 08:27:59

Data from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in San Diego CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined...

2014-01-30 08:31:26

CRANBURY, N.J., Jan. 30, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be presented at the 16(th) Congress of the European Society for Sexual Medicine in Istanbul, Turkey on Friday, January 31, 2014 at 3:25 PM local time. Dr. Michael L. Krychman from Southern California Center for...

2014-01-27 12:29:17

Nearly two-thirds of women polled believe it's inappropriate that the score is 24-0 when it comes to federal approval of treatments for desire, arousal or orgasm dysfunction in men vs. women WASHINGTON, Jan. 27, 2014 /PRNewswire-USNewswire/ -- Almost two-thirds of American women believe that society places a greater emphasis on addressing men's sexual satisfaction than on women's - an opinion underscored by the fact that 24 drugs have received federal approval to treat male sexual...

2013-11-13 16:27:00

CRANBURY, N.J., Nov. 13, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has entered into an option agreement for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union. Palatin...

2013-03-01 08:23:58

Data from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in New Orleans CRANBURY, N.J., March 1, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced bremelanotide 1.25 mg and 1.75 mg doses significantly increased sexual arousal, sexual desire and the number of sexually satisfying events, and decreased associated distress in premenopausal women with female sexual...

2012-11-08 08:34:25

CRANBURY, N.J., Nov. 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD). The data demonstrate that women taking bremelanotide showed statistically significant increases in the number...

2012-09-10 02:28:45

CRANBURY, N.J., Sept. 10, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). Database lock is expected by the end of September and top-line trial results are expected in the first-half of next quarter. "We are pleased to reach this important milestone of completing the patient treatment...

2012-07-23 22:20:44

ALMERE, The Netherlands, July 24, 2012 /PRNewswire/ -- Emotional Brain, a developer of therapeutic products for the treatment of Female Sexual Dysfunction, is pleased to announce that the United States Patent and Trademark Office (USPTO) has awarded a new patent (US Patent No. 8,227,453, issued today) for one of its methods for the treatment of women suffering from Female Sexual Dysfunction (FSD). In view of the importance of proper protection, the award of this patent in the...

2012-03-08 06:30:00

CRANBURY, N.J., March 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced it has completed enrollment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). Over 400 premenopausal women, diagnosed with female sexual arousal disorder, hypoactive sexual desire disorder or both, have been enrolled in the study. Patients, who will undergo 16 weeks of treatment, will be randomized to one...